Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction

International Journal of Impotence Research volume 18, pages 180–185 (2006)Cite this article

Abstract

We have investigated the reliability of intracavernosal prostaglandin E1 (PGE1) office vs self-injection therapy in patients with erectile dysfunction (ED). A total of 298 male patients with ED were enrolled in this study. In all patients, intracavernosal titration of the PGE1 dose was performed. A total of 106 patients were enrolled in the self-injection program, and 192 patients were enrolled in the office injection program. There were significant differences between number of injections and amount of PGE1 per month, total number of injections, and total amount of PGE1 on office and self-injection programs (P<0.05 for each). There was a significant increase in the dropout rate in the office injection group compared with the self-injection group (P<0.05). There was an increase in penile fibrosis in the self-injection program compared with the office program (P<0.05). A self-injection program is reliable. Office injection program can be reserved for a subset of ED patients with special preferences.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Virag R . Intracavernous injection of papaverine for erectile failure (Letter). Lancet 1982; 2: 938.

    Article  CAS  Google Scholar 

  2. Adaikan PG, Kottegoda SR, Ratnam SS . A possible role for prostaglandin E1 in human penile erection. Abstract Book Second World Meeting on Impotence, Prague 1986, Abstr 2.6.

  3. Ishii N, Watanabe H, Irisawa C, Kikuchi Y . Therapeutic trial; with prostaglandin E1 for organic impotence. Abstract Book Second World Meeting on Impotence, Prague 1986 Abstr 11.2.

  4. Stackl W, Hasun R, Marberger M . Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988; 140(1): 66–68.

    Article  CAS  Google Scholar 

  5. Hedlund H, Andersson KE . Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985; 134(6): 1245–1250.

    Article  CAS  Google Scholar 

  6. Palmer LS, Valcic M, Melman A, Giraldi A, Wagner G, Christ GJ . Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 1994; 152(4): 1308–1314.

    Article  CAS  Google Scholar 

  7. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG . Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157(5): 1920–1925.

    Article  CAS  Google Scholar 

  8. El-Sakka AI . Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004; 16: 13–20.

    Article  CAS  Google Scholar 

  9. El-Sakka AI . Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004; 46(4): 503–509.

    Article  CAS  Google Scholar 

  10. Virag R . Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 55: 1073–1077.

    Article  Google Scholar 

  11. Virag R, Shoukry K, Floresco J, Nollet F, Greco E . Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991; 145: 287–292.

    Article  CAS  Google Scholar 

  12. Fallon B . Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 1995; 22: 833–845.

    CAS  Google Scholar 

  13. Porst H . The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155(3): 802–815, Review.

    Article  CAS  Google Scholar 

  14. Sharlip I . Does natural erectile function improve following intracavernous injections of vasoactive drugs? Int J Impot Res 1997; 9(4): 193–196, Review.

    Article  CAS  Google Scholar 

  15. Spisni E, Manica F, Tomasi V . Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot Essent Fatty Acids 1992; 47(2): 111–115.

    Article  CAS  Google Scholar 

  16. Marshall GA, Breza J, Lue TF . Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994; 43(6): 844–848.

    Article  CAS  Google Scholar 

  17. Montorsi F et al. Recovery of spontaneous erections after nerve sparing radical prostatectomy with and without early intracavernous injections of prostaglandin E1: results of a prospective randomized trial. J Urol 1996; 155: 468A.

    Article  Google Scholar 

  18. Padma-Nathan H, Linet O, Sheu W . The impact on return of spontaneous erections of short-term alprostadil therapy post nerve sparing prostatectomy. J Urol 1997; 157(4): 363, (1422A).

    Google Scholar 

  19. McMahon CG . The return of spontaneous erections after self-injection of prostaglandin E1. Int J Impot Res 1992; 4: 179–186.

    Google Scholar 

  20. Aboseif SR, Breza J, Bosch RJ, Benard F, Stief CG, Stackl W et al. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1 and saline in primates. J Urol 1989; 142: 403–408.

    Article  CAS  Google Scholar 

  21. Hwang TI, Yang CR, Ho WL, Chu HW . Histopathological change of corpora cavernosa after long-term intracavernous injection. Eur Urol 1991; 20(4): 301–306.

    Article  CAS  Google Scholar 

  22. Hu KN, Burks C, Christy WC . Fibrosis of tunica albuginea: complications of long-term intracavernous pharmacological self-injection. J Urol 1987; 138(2): 404–405.

    Article  CAS  Google Scholar 

  23. Godschalk MF, Chen J, Katz PG, Mulligan T . Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose–response study. J Urol 1994; 151(6): 1530–1532.

    Article  CAS  Google Scholar 

  24. Amar E, Kobelinsky M, Khoury R, Sarkis P, Bouyer I, Dauphin A et al. Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients. Prog Urol 1993; 3(6): 971–978.

    CAS  PubMed  Google Scholar 

  25. Lakin MM, Montague DK, Schover LR . Fibrosis with intracavernous injection therapy utilizing prostaglandin E1. J Urol 1992; 147(4): 309A.

    Google Scholar 

  26. Chen RN, Lakin MM, Montague DK, Ausmundson S . Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis. J Urol 1996; 155(1): 138–140.

    Article  CAS  Google Scholar 

  27. Chew KK, Stuckey BG, Earle CM, Dhaliwal SS, Keogh EJ . Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997; 9(4): 225–229.

    Article  CAS  Google Scholar 

  28. Kolaja GJ, Kirton KT . Toxocology studies with alprostadil. Symposium on ‘the role of alprostadil in the diagnosis and therapy of erectile dysfunction’. Excerpta Medica 1993; 40–50.

  29. Virag R, Nollet F, Greco E, Shoukry K . Dynamic echography of the penis in the follow-up of impotent patients treated with intracavernous injections. Br J Urol 1993; 72(5): 809–816.

    Article  CAS  Google Scholar 

  30. El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF . The effect of surgical trauma on rat tunica albuginea. J Urol 1998; 159(5): 1700–1707.

    Article  CAS  Google Scholar 

  31. Smith BH . Peyronie's disease. Am J Clin Pathol 1966; 45(6): 670–678.

    Article  CAS  Google Scholar 

  32. Linet OI, Ogrinc FG . Penile fibrosis during 18 months of intracavernosal therapy with alprostadil. Int J Impot Res 1996; 8(3): D85.

    Google Scholar 

  33. Porst H, Buvat J, Meuleman E, Michal V, Wagner G . Intracavernous alprostadil alfadex – an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10(4): 225–231.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, School of Medicine, Suez Canal University, Ismailia, Egypt

    A I El-Sakka

Authors
  1. A I El-Sakka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A I El-Sakka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Sakka, A. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res 18, 180–185 (2006). https://doi.org/10.1038/sj.ijir.3901388

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901388

Keywords

This article is cited by

Search

Advanced search

Quick links